



Supplementary Figure S4: Combining HC-5404 and VEGFR-TKIs does not affect mouse body weight or exposure levels in mouse. A-D) Mouse body weight across 28 days of treatment with four VEGFR-TKI/HC-5404 combinations at indicated dose levels (n=10 mice per group). E) HC-5404 concentration in mouse plasma following oral administration of HC-5404 alone or in combination with sunitinib. Mouse plasma sampled at 1 h following the final oral administration after 15 days of treatment. HC-5404 concentration determined by LC-MS/MS. F) Sunitinib concentration in mouse plasma following treatment alone or in combination with HC-5404. Sunitinib dosed at 40 mg/kg, PO, QD, and HC-5404 orally administered BID at the indicated dose for 15 days. Sunitinib concentration determined by LC-MS/MS